Article

Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease

European journal of nuclear medicine and molecular imaging (impact factor: 4.99). 04/2012; 37(8):1575-1593. DOI:10.1007/s00259-009-1301-z pp.1575-1593

ABSTRACT Alzheimer’s disease (AD) is a common degenerative neurological disease that is an increasing medical, economical, and social
problem. There is evidence that a long “asymptomatic” phase of the disease exists where functional changes in the brain are
present, but structural imaging for instance with magnetic resonance imaging remains normal. Positron emission tomography
(PET) is one of the tools by which it is possible to explore changes in cerebral blood flow and metabolism and the functioning
of different neurotransmitter systems. More recently, investigation of protein aggregations such as amyloid deposits or neurofibrillary
tangles containing tau-protein has become possible. The purpose of this paper is to review the current knowledge on various
18F- and 11C-labelled PET tracers that could be used to study the pathophysiology of AD, to be used in the early or differential diagnosis
or to be used in development of treatment and in monitoring of treatment effects.

KeywordsAD-Alzheimer’s disease-Cognition-Positron emission tomography-PET-
11C-
18F

0 0
 · 
1 Bookmark
 · 
51 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

11C-labelled PET tracers
 
amyloid deposits
 
cerebral blood flow
 
common degenerative neurological disease
 
current knowledge
 
different neurotransmitter systems
 
differential diagnosis
 
functional changes
 
KeywordsAD-Alzheimer’s disease-Cognition-Positron emission tomography-PET-
 
magnetic resonance imaging
 
protein aggregations
 
structural imaging
 
tau-protein
 
treatment effects
 
“asymptomatic” phase